Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of TPF induction regimens followed by cetuximab-based radiotherapy versus PF-HART chemoradiation in unresectable head and neck squamous cell carcinoma
2010-019347-18Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Apr 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, cisplatin, fluorouracil and cetuximab in head and neck squamous cell carcinoma (HNSCC), Oral Mucosal Carcinoma, oropharyngeal squamous cell carcinoma (OPSCC) and 1 more (3 arms), sponsored by Charité – Universitätsmedizin Berlin. Started Apr 2010; status: completed.
02
Drugs
docetaxelcisplatinfluorouracilcetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Oral Mucosal Carcinomaoropharyngeal squamous cell carcinoma (OPSCC)squamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on 2010-019347-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019347-18.